Eli Lilly (LLY) reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs 澳洲幸运5官方开奖结果体彩网:Mounjaro and Zepbound.

The drugmaker is projected to report $9.97 billion in revenue, a 20% bump from last year's mark of $8.31 billion, with 澳洲幸运5官方开奖结果体彩网:net income also projected to rise over 35% to $2.39 billion from $1.76 billion a year ago, according to estimates compiled by Visible Alpha.

Key Metric: Mounjaro, Zepbound Sales

Demand for the weight-loss drugs has boosted the revenue and shares of Eli Lilly along with 澳洲幸运5官方开奖结果体彩网:Ozempic and W📖egovy-maker Novo Nordisk (NVO) o💯ver the past year, as the companies have increased production capacity to meet demand.

In its 澳洲幸运5官方开奖结果体彩网:first-quarter report, Eli Lilly lifted its🌳 revenue and profit projections for the full year due to strong sales 🍌for the weight-loss drugs.

JPMorgan analysts wrote Monday that Eli Lilly remains one of their "core holdings" in the pharmaceutical space, especially as the stock has fallen in recent weeks amid a 澳洲幸运5官方开奖结果体彩网:market-wide rotation out of some of the largest stocks on the market..

Business Spotlight: Inc🍷reasing Weight-Loss Competition

Eli Lilly and Novo Nordisk's dominance in the weight-loss space could be challenged in the coming quarters as drugs from competitors like 澳洲幸运5官方开奖结果体彩网:Viking Therapeutics (VKTX) and 澳洲幸运5官方开奖结果体彩网:Swiss drugmaker Roche have showed positive results in early trials. Telehealth company Hims & Hers Health (HIMS) 澳洲幸运5官方开奖结果体彩网:announced its own weight-loss offerings in the quarter, potenti🙈ally at a lower cost than pop🥂ular drugs like Ozempic and Mounjaro.

JPMorgan analysts said they believe Eli Lilly and Novo Nordisk are likely to "remain dominant" in the weight loss space going forward despite increased competition. They continue to see "significant upside" to Mounjaro and Zepbound sales.

Eli Lilly shares were up 1.8% Wednesday to above $804, more than 37% above where they started the year, but down from 🐠record levels seen earlier this ﷽month.